TSBX – turnstone biologics corp. (US:NASDAQ)

News

Turnstone Biologics Corp. (NASDAQ: TSBX) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating.
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics Corp. (NASDAQ: TSBX) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com